Madrigal Pharmaceuticals, Inc. MDGL Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Operating margin | -27.7%+3.6pp | -31.3%+10.2pp | -41.5%+18.6pp | -60.1%+73.9pp | -134%— | |
| Net margin | -27.3%+2.8pp | -30.1%+9.0pp | -39%+15.6pp | -54.7%+68.7pp | -123.4%— | |
| EBITDA margin | -27.5%+3.6pp | -31.2%+10.2pp | -41.3%+18.5pp | -59.8%+73.7pp | -133.5%— | |
| Returns | ||||||
| Return on equity | -49.3%-6.9pp | -42.5%-1.3pp | -41.2%-4.9pp | -36.3%+13.9pp | -50.2%+30.2pp | |
| Return on assets | -27.8%-2.8pp | -25%-1.3pp | -23.7%+2.9pp | -26.7%+11.0pp | -37.7%+17.7pp | |
| Return on invested capital | -46.7%-7.1pp | -39.6%+5.2pp | -44.8%+10.1pp | -54.9%+29.1pp | -84%-0.4pp | |
| Efficiency | ||||||
| Asset turnover | 1×+0.2× | 0.8×+0.2× | 0.6×+0.1× | 0.5×+0.2× | 0.3×+0.1× | |
| Liquidity | ||||||
| Current ratio | 3.5×-0.5× | 4×+0.6× | 3.4×-1.7× | 5.1×-0.8× | 5.9×-0.2× | |
| Quick ratio | 3.2×-0.6× | 3.8×+0.5× | 3.3×-1.5× | 4.8×-0.8× | 5.6×-0.3× | |
| Cash ratio | 0.7×0.0× | 0.7×-0.1× | 0.8×-0.2× | 1×-0.2× | 1.1×+0.5× | |
| Leverage | ||||||
| Debt-to-equity | 0.7×+0.1× | 0.6×0.0× | 0.6×+0.4× | 0.2×0.0× | 0.2×0.0× | |
| Debt-to-assets | 0.3×0.0× | 0.3×0.0× | 0.3×+0.1× | 0.1×0.0× | 0.1×0.0× | |
| Interest coverage | -11.7×+1.8× | -13.5×+4.1× | -17.6×+5.0× | -22.5×+7.5× | -30.1×+3.8× | |
| Per Share | ||||||
| Book value per share | $18.72-11.8% | $21.21-3.3% | $21.95-11.0% | $24.65-2.6% | $25.30-9.7% | |
| Valuation | ||||||
| Market capitalization | $12.01B-9.2% | $13.23B+29.4% | $10.22B+61.6% | $6.33B-13.5% | $7.31B+8.7% | |
| Enterprise value | $12.15B-9.1% | $13.37B+29.8% | $10.3B+64.2% | $6.27B-13.6% | $7.26B+7.6% | |
| Price / sales | 10.6×-3.2× | 13.8×0.0× | 13.8×+1.5× | 12.3×-10.8× | 23×— | |
| Price / book | 22.1×+0.2× | 21.9×+5.6× | 16.3×+7.2× | 9.1×-1.2× | 10.3×+1.4× | |
| EV / sales | 10.7×-3.2× | 13.9×0.0× | 13.9×+1.7× | 12.2×-10.7× | 22.9×— | |
| Earnings yield | -2.6%-0.4pp | -2.2%+0.6pp | -2.8%+1.6pp | -4.5%+0.9pp | -5.4%+1.6pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Madrigal Pharmaceuticals, Inc.'s profit margins?
- Madrigal Pharmaceuticals, Inc. (MDGL) runs a 96.5% gross margin and a -27.7% operating margin, with a -27.3% net margin.
- Where do Madrigal Pharmaceuticals, Inc.'s ratios come from?
- Every ratio is computed from Madrigal Pharmaceuticals, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
